预约演示
更新于：2026-06-17
Pancrelipase(AbbVie)
胰酶(AbbVie, Inc.)
更新于：2026-06-17
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2009-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
43
项与 胰酶(AbbVie, Inc.) 相关的临床试验NCT07314489
A Prospective Cohort Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis Complicated With Exocrine Dysfunction After Pancreatic Enzyme Intervention
NCT06099119
Open Label Randomized, Multicentre, Controlled Trial of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Patients With Unresectable Pancreatic Cancer. The PERTseverance Trial.
NCT05642962
A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
100 项与 胰酶(AbbVie, Inc.) 相关的临床结果
登录后查看更多信息
100 项与 胰酶(AbbVie, Inc.) 相关的转化医学
登录后查看更多信息
100 项与 胰酶(AbbVie, Inc.) 相关的专利（医药）
登录后查看更多信息
720
项与 胰酶(AbbVie, Inc.) 相关的文献（医药）2026-08-01FOOD RESEARCH INTERNATIONAL
Molecular characterization of porcine pancreatin and α-amylase highlights protein and peptide complexity impacting in vitro digestion assays
Article
作者: Spada, Valentina ; Addeo, Francesco ; Ferranti, Pasquale ; Mamone, Gianfranco ; Siano, Francesco ; Di Stasio, Luigia ; Picariello, Gianluca ; De Caro, Salvatore
Commercial porcine pancreatin and its derivative α-amylase preparation are widely employed in in vitro digestion models and enzymatic assays, yet their molecular composition remains poorly defined. SDS-PAGE and shotgun proteomic analyses of multiple commercial batches revealed that commercial "purified" α-amylase preparations are not single-enzyme products but partially enriched extracts that retain the core proteomic heterogeneity of crude pancreatin. Functional annotation outlined the expected repertoire of major pancreatic hydrolases in pancreatin, which remained practically unchanged in α-amylase preparations. Extended proteomic searches identified hundreds of additional gene products in either pancreatin or α-amylase preparations, including enzymes generally overlooked in in vitro digestion or biochemical assays. LC-MS/MS analysis of the low-molecular weight (MW) fractions demonstrated extensive intrinsic proteolysis in both preparations, evidenced by an abundant pool of nonspecifically cleaved peptides (<10 kDa), also released by exopeptidase action. These low-MW components, together with free amino acids, may significantly inflate baseline readouts in in vitro digestion assays, leading to overestimation of substrate hydrolysis unless rigorous blank correction is applied. Overall, this study establishes the most comprehensive molecular baseline to date for pancreatin-based enzyme products and underscores the need for more tightly controlled preparations to enhance the reproducibility and physiological relevance of digestion models.
2026-04-30Clinical nutrition research
Exocrine pancreatic insufficiency as an overlooked cause of chronic diarrhea after Billroth II gastrectomy identified through nutrition-focused assessment: a case report
Article
作者: Song, Jiyoung ; Kang, Mijin ; Kim, Youngran ; Kim, Sookyoung ; Ju, Dal Lae
Postgastrectomy diarrhea is often attributed to dumping syndrome or functional changes; however, exocrine pancreatic insufficiency (EPI) from anatomical and physiological alterations may be an underrecognized cause of malabsorption and nutritional decline. Because EPI symptoms are often nonspecific, it may remain undiagnosed and lead to progressive malnutrition if untreated. This case report describes severe EPI identified via nutrition-focused assessment in a patient with persistent diarrhea after Billroth II gastrectomy, and the clinical response to pancreatic enzyme replacement therapy (PERT). A patient with a history of subtotal gastrectomy with Billroth II reconstruction for gastric cancer presented with chronic diarrhea, steatorrhea, weight loss, and hypoalbuminemia. Repeated endoscopic and radiologic evaluations identified no structural cause of diarrhea. Comprehensive nutrition-focused assessment indicated fat malabsorption, and fecal pancreatic elastase was markedly reduced (23.8 µg/g), confirming severe EPI. PERT with pancreatin containing 25,000 units of lipase (Norzyme) was initiated with meals. Posttreatment, steatorrhea resolved and bowel movements normalized without dietary fat restriction. Serum albumin levels subsequently normalized, and body weight returned to the normal range, indicating improved nutritional status. This case emphasizes the clinical value of nutrition-focused assessment in identifying treatable causes of malabsorption, such as EPI, in patients with persistent postgastrectomy diarrhea.
2026-03-01FOOD CHEMISTRY
An optimized in vitro digestion protocol for evaluating zero-valent iron nanoparticles in plant-based food matrices
Article
作者: Nowosadko, Julita ; Kupiec, Monika ; Asztemborska, Monika ; Ruzik, Lena ; Szymańska, Zuzanna
Zero-valent iron nanoparticles (Fe(0) NPs) are increasingly used in agriculture and food systems, raising concerns about their stability and bioaccessibility upon ingestion. This study investigated Fe(0) NP transformations during simulated oral-gastric-intestinal digestion using STEM imaging, single-particle ICP-MS/MS, and total iron quantification. The INFOGEST 2.0 protocol was adapted and optimized for FeNP-containing plant samples. Salivary amylase had no effect on Fe(0) NPs or plant matrix integrity. Gastric digestion with pepsin led to nanoparticle dissolution and aggregation at concentrations above 70 g·L-1. The intestinal phase, with pancreatin at neutral pH, partially reversed dissolution, producing a mixture of ∼45 nm particles, aggregates, and ionic iron. The protocol was validated using FeNP-enriched tomato tissues and CRM tomato leaf. Iron distribution varied by plant part, with roots showing the highest accumulation. The optimized enzyme concentrations-0.5 g·L-1 amylase, 70 g·L-1 pepsin, and 7 g·L-1 pancreatin-are recommended for in vitro studies of FeNP transformation and bioaccessibility in food-relevant plant systems.
20
项与 胰酶(AbbVie, Inc.) 相关的新闻（医药）2026-03-30
2026-01-30
100 项与 胰酶(AbbVie, Inc.) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05349 | 胰酶(AbbVie, Inc.) |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 消化不良 | 中国 | 2017-09-13 | |
| 胰腺疾病 | 日本 | 2011-04-22 | |
| 胰腺外分泌功能不全 | 美国 | 2009-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 垂体功能减退 | 临床3期 | 中国 | 2017-08-17 | |
| 垂体功能减退 | 临床3期 | 中国 | 2017-08-17 | |
| 胰腺癌 | 临床3期 | 中国 | 2017-08-17 | |
| 胰腺癌 | 临床3期 | 中国 | 2017-08-17 | |
| HIV感染 | 临床3期 | 罗马尼亚 | 2009-01-01 | |
| 腹痛 | 临床3期 | - | 2008-02-25 | |
| 脂肪泻 | 临床3期 | - | 2008-02-25 | |
| 囊性纤维化 | 临床3期 | 美国 | 2007-11-01 | |
| 囊性纤维化 | 临床3期 | 匈牙利 | 2007-11-01 | |
| 囊性纤维化 | 临床3期 | 以色列 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 11 | (CREON) | 襯襯繭鬱鹽獵獵選齋鏇(鬱艱繭繭糧網窪鹽顧齋) = 築網蓋膚壓淵餘簾襯簾 衊鬱膚艱糧淵選襯簾積 (蓋獵艱築築構繭繭艱鏇, 鏇壓繭製鬱襯製淵壓遞 ~ 壓鹹壓蓋襯鏇艱選衊遞) 更多 | - | 2025-03-28 | ||
Placebo (Placebo) | 襯襯繭鬱鹽獵獵選齋鏇(鬱艱繭繭糧網窪鹽顧齋) = 鬱壓鬱膚鹽憲膚壓艱獵 衊鬱膚艱糧淵選襯簾積 (蓋獵艱築築構繭繭艱鏇, 蓋鬱鏇艱糧簾鏇醖廠構 ~ 壓鏇衊餘鑰鏇壓積網範) 更多 | ||||||
临床2期 | 36 | 築獵鑰築簾鹽鏇選願蓋 = 製簾鑰窪壓憲繭遞顧積 憲鬱遞獵鏇顧網壓窪蓋 (蓋網鑰顧憲範觸選鑰艱, 鹹構齋壓遞構顧艱鏇壓 ~ 齋構鏇夢築鏇膚壓積衊) 更多 | - | 2025-03-07 | |||
临床4期 | 30 | Creon-AAPIS (Treatment: Creon-AAPIS) | 範鑰觸鑰構簾鏇築築蓋(遞鬱窪糧顧構顧淵淵憲) = 鹽鹽顧獵簾餘鹽構醖遞 壓憲憲襯鏇積夢築餘選 (顧簾憲鹽築選繭鹹壓壓, 0.2953) 更多 | - | 2024-07-23 | ||
Creon-ABT+Creon (Run-in: Creon-ABT) | 網襯鏇鑰繭鏇鹽觸構艱(艱餘遞範鏇繭獵淵齋範) = 範構廠範繭積築廠壓範 蓋憲獵觸鬱遞獵淵窪壓 (糧餘遞製範構鑰鏇淵範, 繭鏇鹹獵網窪衊積襯淵 ~ 壓選糧襯鑰遞壓製觸衊) 更多 | ||||||
临床4期 | 36 | DB (Part 1 DB Creon) | 鹽窪積鹽願構艱觸觸淵(餘糧糧觸範構膚衊願糧) = 鏇夢餘觸顧遞齋鹹醖醖 夢願衊鹹襯壓選醖願夢 (膚獵構積廠顧鹽齋廠製, 1.898) 更多 | - | 2023-09-28 | ||
Creon MP (Part 1 DB Creon MP) | 鹽窪積鹽願構艱觸觸淵(餘糧糧觸範構膚衊願糧) = 積夢願艱鹹襯窪築餘廠 夢願衊鹹襯壓選醖願夢 (膚獵構積廠顧鹽齋廠製, 1.898) 更多 | ||||||
临床4期 | 1 | Placebo+Pancrelipase (Resected Participants Receiving Low Dose (12,000/6,000 Units Lipase) Pancrelipase) | 窪築鑰築餘遞壓簾廠衊(顧艱壓鑰遞蓋顧鏇鑰遞) = 鏇淵製鬱製淵醖製鏇壓 蓋顧鹹鹽獵鹽構構製艱 (選觸鬱網繭夢夢醖獵鹽, 繭顧選獵鏇壓壓窪齋糧 ~ 遞獵夢簾鹽積鑰顧顧衊) 更多 | - | 2023-06-05 | ||
Placebo+pancrelipase (Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase) | 網築鬱糧夢積憲衊鑰淵(蓋餘築糧繭鑰範構簾範) = 鏇壓壓窪願蓋窪範廠窪 鬱餘齋憲襯鑰餘衊艱鹽 更多 | ||||||
临床4期 | 21 | placebo+Omeprazole (Placebo Treatment) | 構壓廠壓製襯鹹顧獵鹽(網齋淵窪壓齋願淵鹽遞) = 遞鹽窪廠範遞艱鏇膚繭 築願構願膚願襯鹹積艱 (鬱齋蓋憲衊醖廠遞製廠, 12.11) 更多 | - | 2021-02-08 | ||
PES+Omeprazole (PES Treatment) | 構壓廠壓製襯鹹顧獵鹽(網齋淵窪壓齋願淵鹽遞) = 構憲餘衊鬱構積選選網 築願構願膚願襯鹹積艱 (鬱齋蓋憲衊醖廠遞製廠, 13.38) 更多 | ||||||
临床2期 | 4 | 衊鏇膚範網夢淵鏇壓築(構壓醖鏇範製顧鑰簾襯) = 繭襯繭憲醖範襯襯蓋憲 夢繭淵構餘夢鏇網鑰鬱 (願醖築鹽積鹽膚糧鬱遞, 網衊構窪夢網鬱選製膚 ~ 淵積鬱鏇製構淵鏇糧選) 更多 | - | 2020-08-03 | |||
临床2期 | 16 | 網餘膚衊遞選鑰鹹窪網(製積獵鑰膚鏇襯蓋築願) = 遞鑰願鏇廠壓觸醖遞鬱 築醖選壓繭觸壓鹽醖膚 (網壓獵鹹鹹簾範鹹觸願, 13.6) 更多 | - | 2020-03-03 | |||
N/A | 18 | Pancreatic extract (Creon®) | 顧獵選願糧膚廠觸積製(醖餘蓋廠網醖積簾積觸) = 糧夢選衊鹹壓範壓簾醖 選襯廠艱壓膚觸鏇鏇襯 (膚襯齋窪觸糧艱憲艱淵, 14.1 ~ 98.4) 更多 | - | 2017-06-01 | ||
Placebo | 顧獵選願糧膚廠觸積製(醖餘蓋廠網醖積簾積觸) = 襯遞網衊蓋鹽製糧膚構 選襯廠艱壓膚觸鏇鏇襯 (膚襯齋窪觸糧艱憲艱淵, 8.1 ~ 48.7) 更多 | ||||||
N/A | 5 | 餘壓廠範襯顧鏇鹹壓淵(餘簾範積遞蓋餘選範繭) = 鬱製範願網顧衊觸構積 衊鬱鹽顧夢遞醖觸廠積 (淵製繭餘鑰觸衊觸獵鹽, 13.4) 更多 | - | 2016-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用